1.The etiology and classification of hemangioma is the most common benign tumor in infancy and early childhood, with an incidence of 10~12 and a male to female ratio of about 1:3~5. There is a typical process of occurrence, development and self-resolution of hemangioma in infants and young children, which is usually clinically divided into three phases: proliferation phase (0~1 year old), stabilization phase (1~2 years old) and receding phase (2~7 years old). The tumor begins to be gradually replaced by fibrofatty tissue. However, clinically, hemangiomas grow in different ways, with some growing slowly and others growing very rapidly and unpredictably. The pathogenesis of infantile hemangiomas remains unclear and is more common in premature and low birth weight infants. Various studies in recent years suggest that the occurrence of hemangiomas may be associated with advanced maternal age, multiple pregnancies, placenta praevia and pre-eclampsia. Chorionic villus sampling of the chorionic villi during pregnancy is a higher risk factor for the development of hemangiomas. The pathogenesis of hemangiomas remains unclear, leading to many controversies in their classification. Previously, hemangiomas were clinically classified into capillary hemangioma, strawberry hemangioma, cavernous hemangioma, trabecular hemangioma and mixed hemangioma according to the morphology of the lesion, but this classification method failed to reflect the pathological nature of the lesion and was of little value for clinical treatment. 1982 Mulliken et al. conducted an in-depth study on the biological characteristics of hemangioma vascular endothelial cells and divided them into two categories: one category of vascular endothelial cells with In 1988, the Hamburg International Symposium of the International Society for the Study of Vascular Diseases (ISSVA) established the modern Hamburg classification on the basis of Mulliken’s classification, which has guiding significance for the treatment of hemangioma. Finn et al. pointed out that the earlier the degeneration of hemangioma occurs, the more complete the degeneration. In the author’s opinion, as the material and cultural level of China continues to grow, people’s requirements for hemangioma treatment also continue to improve, and we have proposed the concept of “perfect” treatment. In other words, we use non-invasive or minimally invasive methods to inhibit the growth of hemangioma, promote its degeneration, reduce the incidence of complications, and leave no traces of hemangioma, so that it can be perfectly cured. Most infantile hemangiomas do not have serious complications, but about 12% of children suffer from bleeding, ulceration, visual impairment, deformity, respiratory blockage, congestive heart failure or even death. There are many treatment options for hemangioma, including bandage compression, medication (propranolol), topical application of timolol maleate eye drops, polyglactin injection, laser, interventional procedures, etc. We recommend that giant hemangiomas (generally R125px in diameter, or with bleeding or rupture R75px) should be treated with TASE within 6 months and oral propranolol for 3 to 6 months after surgery. Small lesions protruding from the skin surface can be injected with polyglaucine, those with small areas that are relatively superficial can be coated with timolol eye drops, and multiple hemangiomas are controlled with propranolol. These methods can be used in combination, and for specific cases, professional medical guidance is needed.